mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|7|945-954

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.7, 2012-03, pp. : 945-954

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

By Prichard Mark   Harris Thomas   Williams Michael E   Densmore John J  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 983-995

Informa Healthcare

Access to resources Recommend Favorite

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 174-181

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR Inhibition in Lymphoma: A Rational and Promising Strategy

By  

Letters in Drug Design & Discovery, Vol. 4, Iss. 3, 2007-04 ,pp. : 224-231

Bentham Science Publishers

Access to resources Recommend Favorite

Lenalidomide offers effective treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

The mTOR protein as a target in thyroid cancer

By Souza Elaine Cristina Lima de   Ferreira Andrea Claudia Freitas   Carvalho Denise Pires de  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 9, 2011-09 ,pp. : 1099-1112

Informa Healthcare

Access to resources Recommend Favorite